Past and prognosis of anti-VEGF therapy for wet age-related macular degeneration—the future has begun
- 84 Downloads
We would like to thank Dan and Mihai Călugăru for their critical interest in our recently published work . This gives us the opportunity to address the remarkable improvements that have been achieved by adopting ideal world outcomes in the therapy of exudative or wet age-related macular degeneration (AMD) using ranibizumab to the real world possibilities.
Ranibizumab was the first drug approved for the prevention of vision loss in wet AMD in 2006. The ophthalmological community believed that now a bright future had begun. Indeed, its approval revolutionized ophthalmology and opened the treatment floor for a group of vascular diseases affecting the macula that had been perceived widely untreatable by then. As we have meanwhile learned, beneficial anti-VEGF effects reach not only the macula, but eventually the entire retina .
Compliance with ethical standards
Conflict of interest
JGG acts as an advisor to diverse pharmaceutical companies and contributes to several clinical studies. Nevertheless, none of the authors have received direct or indirect financial support for this study or have a conflicting interest with the data that are presented in the report.
For this type of study formal consent is not required.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 7.Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Hykin P, Staurenghi G, Wittrup-Jensen K, Altemark A, Nilsson J, Kim K, Sivaprasad S (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol 100:1623–1628CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO, European Society for Retina Specialists’ Guidelines Committee (EURETINA) (2007) Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 85:486–494CrossRefPubMedGoogle Scholar
- 11.Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, Sustain Study Group (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 118:663–671CrossRefPubMedGoogle Scholar
- 12.Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of Neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:1751–1761CrossRefGoogle Scholar
- 15.Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F, European Society of Retina Specialists (2014) Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 98:1144–1167CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Lanzetta P, Loewenstein A, Vision Academy Steering Committee (2017) Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol 255:1259–1273CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR, TREX-AMD Study Group (2015) Prospective trial of treat-and-extend versus monthly dosing for Neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology 122:2514–2522CrossRefPubMedGoogle Scholar
- 23.Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS (2016) A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 100:914–917 Though our study suggests superiority of the treat and extend regimen to PRN treatment in a 12-month period, this review demonstrates the need for randomised clinical trials to confirm our findings and to evaluate long-term efficacy outcomes with these regimens compared with monthly therapyCrossRefPubMedGoogle Scholar
- 24.Schlottmann PG, Alezzandrini AA, Zas M, Rodriguez FJ, Luna JD, Wu L (2017) New treatment modalities for Neovascular age-related macular degeneration. Asia Pac J Ophthalmol (Phila) 6:514–519Google Scholar
- 25.Mehta H, Tufail A, Daien V, Lee AY, Nguyen V, Ozturk M, Barthelmes D, Gillies MC (2018) Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Prog Retin Eye Res pii S1350-9462(17):30105–30102Google Scholar